OLD Second National Bank of Aurora Has $2.76 Million Position in Danaher Co. (NYSE:DHR)

OLD Second National Bank of Aurora boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 1.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,943 shares of the conglomerate’s stock after acquiring an additional 193 shares during the period. OLD Second National Bank of Aurora’s holdings in Danaher were worth $2,763,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of DHR. BKM Wealth Management LLC acquired a new position in shares of Danaher in the 4th quarter valued at $27,000. OFI Invest Asset Management bought a new stake in Danaher in the 3rd quarter valued at $30,000. First Capital Advisors Group LLC. bought a new stake in Danaher in the 2nd quarter valued at $32,000. BOK Financial Private Wealth Inc. bought a new stake in Danaher in the 3rd quarter valued at $34,000. Finally, Nalls Sherbakoff Group LLC bought a new stake in Danaher in the 3rd quarter valued at $37,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, Director Teri List sold 3,289 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,957 shares of company stock valued at $8,265,802. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

DHR stock traded down $1.47 during mid-day trading on Thursday, hitting $237.92. The company had a trading volume of 1,463,341 shares, compared to its average volume of 2,689,187. The firm has a market cap of $176.19 billion, a PE ratio of 37.46, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The stock’s fifty day moving average price is $249.28 and its two-hundred day moving average price is $229.86.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue was down 10.2% on a year-over-year basis. During the same quarter last year, the company earned $2.87 earnings per share. On average, analysts forecast that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

Analyst Upgrades and Downgrades

Several brokerages have commented on DHR. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price target for the stock from $250.00 to $280.00 in a research report on Wednesday. KeyCorp boosted their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. JPMorgan Chase & Co. upped their price target on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Finally, Raymond James upped their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $268.27.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.